Skip to main content

View full-text article in PMC

. Author manuscript; available in PMC: 2019 Jul 31.

Published in final edited form as: Circulation. 2018 Jul 31;138(5):513–526. doi: 10.1161/CIRCULATIONAHA.117.031635

Table 4.

Characterization of Heart Failure in Mice Treated with Endoglin Neutralizing Antibody

	IgG Sham	IgG TAC	Sham Eng NAb	Eng NAb TAC
Mass
Total body weight (g)	28.5 ± 1	24.6 ± 4.9	28.3 ± 1.4	27.6 ± 1.2
LV mass (mg)	83 ± 7	206 ± 12^*	86 ± 4	158 ± 12 ^†^‡
Lung mass (mg)	143 ± 6	405 ± 120^*	151 ± 8	176 ± 22^‡
Tibia length (mm)	17.3 ± 0.1	17.7 ± 0.2	17.4 ± 0.2	17.7 ± 0.1
LV/TL (mg/mm)	4.8 ± 0.4	11.6 ± 0.8^*	4.9 ± 0.2	8.9 ± 0.7^†^‡
Lung/TL (mg/mm)	8.3 ± 0.4	22.9 ± 6.9^*	8.7 ± 0.3	9.9 ± 1.3^†^‡
Hemodynamic data
Peak systolic pressure (mmHg)	95 ± 8	119 ± 6^*	92 ± 6	172 ± 19^†
End diastolic pressure (mmHg)	3 ± 2	25 ± 5^*	2 ± 3	6 ± 4^‡
dP/dT max (mmHg/sec)	8249 ± 596	4786 ± 985^*	9119 ± 428	8941 ± 1489^‡
dP/dT min (mmHg/sec)	8382 ± 576	4432 ± 824^*	8681 ± 514	9250 ± 1684^‡
Ejection fraction (%)	61 ± 12	26 ± 8^*	63 ± 7	49 ± 10^†^‡
Heart rate (bpm)	506 ± 26	518 ± 15	526 ± 23	490 ± 17

Means±SD. p<0.05:

^*

vs. IgG Sham;

^†

vs. Eng NAb Sham;

^‡

vs. IgG TAC